Stocks and Investing Stocks and Investing
Thu, August 2, 2018
Wed, August 1, 2018

Matthew Harrison Upgraded (SRPT) to Buy on, Aug 1st, 2018


Published on 2024-10-26 07:32:28 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy on, Aug 1st, 2018.

Matthew has made no other calls on SRPT in the last 4 months.



There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018


These are the ratings of the 7 analyists that currently disagree with Matthew


  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Thursday, June 21st, 2018
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $205 on, Thursday, June 21st, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $196 on, Wednesday, June 20th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $267 on, Tuesday, June 19th, 2018
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
Contributing Sources